A new trial
It's a Phase I/II https://www.clinicaltrials.gov/ct2/show/NCT01976585
The hypothesis is that this novel in situ vaccination will induce clinical responses at distant and untreated tumour sites. There will be two cohorts of patients with either previously untreated or relapsed/refractory iNHL (n=15 per group).
Intratumoral CDX-301 (Flt3L) is injected on days 1-5 and 8-11. This helps recruit and expand a range of different dendritic cell populations in the tumour microenvironment. These cells are uniquely able to endocytose dying cancer cells and cross-present to CD8+ T-cells. On days 11-12 low dose radiotherapy (2Gy) is used to cause immunogenic cell death. Then, starting on day 12 poly-ICLC is injected weekly (x8) to activate DCs.